Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2005 Mar 11

PMID 15757556

Citations 104

Authors

Nigel J Temperton

Paul K Chan

Graham Simmons

Maria C Zambon

Richard S Tedder

Yasuhiro Takeuchi

Robin A Weiss

Affiliations

Soon will be listed here.

Abstract

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.

Citing Articles

Non-Conventional Prognostic Markers in Life-Threatening COVID-19 Cases-When Less Is More.

Rozanovic M, Varady-Szabo K, Domokos K, Kiss T, Loibl C, Marovics G J Clin Med. 2024; 13(18).

PMID: 39336857 PMC: 11432304. DOI: 10.3390/jcm13185369.

Can human IgG subclasses distinguish between confirmed and unconfirmed SARS-CoV-2 infections?.

Mohamed Bahgat M, Hassan Nasraa M, Nadeem R, Amer K, Hassan W, Abd El-Raouf A J Genet Eng Biotechnol. 2024; 22(3):100399.

PMID: 39179319 PMC: 11345650. DOI: 10.1016/j.jgeb.2024.100399.

Ginger ring compounds as an inhibitor of spike binding protein of alpha, beta, gamma and delta variants of SARS-CoV-2: An study.

Hasan T, Naqvi S, Rehman M, Ullah R, Ammad M, Arshad N Narra J. 2024; 3(1):e98.

PMID: 38455706 PMC: 10919719. DOI: 10.52225/narra.v3i1.98.

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.

Cantoni D, Wilkie C, Bentley E, Mayora-Neto M, Wright E, Scott S Front Immunol. 2023; 14:1184362.

PMID: 37790941 PMC: 10544934. DOI: 10.3389/fimmu.2023.1184362.

Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19.

Barrios M, Nicholson S, Bull R, Martinello M, Rawlinson W, Mina M Microorganisms. 2023; 11(8).

PMID: 37630545 PMC: 10458948. DOI: 10.3390/microorganisms11081985.

References

Berry J, Jones S, Drebot M, Andonov A, Sabara M, Yuan X . Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods. 2004; 120(1):87-96. PMC: 7119589. DOI: 10.1016/j.jviromet.2004.04.009. View

Buchholz U, Bukreyev A, Yang L, Lamirande E, Murphy B, Subbarao K . Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004; 101(26):9804-9. PMC: 470755. DOI: 10.1073/pnas.0403492101. View

Han D, Kim H, Kim Y, Poon L, Cho M . Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 2004; 326(1):140-9. PMC: 7127165. DOI: 10.1016/j.virol.2004.05.017. View

Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo M . An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004; 10(8):871-5. PMC: 7095806. DOI: 10.1038/nm1080. View

Giroglou T, Cinatl Jr J, Rabenau H, Drosten C, Schwalbe H, Doerr H . Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol. 2004; 78(17):9007-15. PMC: 506966. DOI: 10.1128/JVI.78.17.9007-9015.2004. View

Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z . Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 2004; 190(6):1119-26. PMC: 7199490. DOI: 10.1086/423286. View

Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F . In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259):263-7. DOI: 10.1126/science.272.5259.263. View

Chen W, Xu Z, Mu J, Yang L, Gan H, Mu F . Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Microbiol. 2004; 53(Pt 5):435-438. DOI: 10.1099/jmm.0.45561-0. View

Towers G, Bock M, Martin S, Takeuchi Y, Stoye J, Danos O . A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A. 2000; 97(22):12295-9. PMC: 17335. DOI: 10.1073/pnas.200286297. View

10.

Kim Y, Lee M, Han D, Cho M . Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses. 2002; 17(18):1715-24. DOI: 10.1089/08892220152741414. View

11.

Depil S, Roche C, Dussart P, Prin L . Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia. 2002; 16(2):254-9. DOI: 10.1038/sj.leu.2402355. View

12.

Besnier C, Takeuchi Y, Towers G . Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A. 2002; 99(18):11920-5. PMC: 129369. DOI: 10.1073/pnas.172384599. View

13.

Sanders D . No false start for novel pseudotyped vectors. Curr Opin Biotechnol. 2002; 13(5):437-42. DOI: 10.1016/s0958-1669(02)00374-9. View

14.

Rota P, Oberste M, Monroe S, Nix W, Campagnoli R, Icenogle J . Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003; 300(5624):1394-9. DOI: 10.1126/science.1085952. View

15.

Li G, Chen X, Xu A . Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003; 349(5):508-9. DOI: 10.1056/NEJM200307313490520. View

16.

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View

17.

Bartosch B, Bukh J, Meunier J, Granier C, Engle R, Blackwelder W . In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A. 2003; 100(24):14199-204. PMC: 283569. DOI: 10.1073/pnas.2335981100. View

18.

Gao W, Tamin A, Soloff A, DAiuto L, Nwanegbo E, Robbins P . Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003; 362(9399):1895-6. PMC: 7112457. DOI: 10.1016/S0140-6736(03)14962-8. View

19.

Grant P, Garson J, Tedder R, Chan P, Tam J, Sung J . Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med. 2003; 349(25):2468-9. DOI: 10.1056/NEJM200312183492522. View

20.

Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W . Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun. 2004; 315(2):439-44. PMC: 7111169. DOI: 10.1016/j.bbrc.2004.01.076. View